[The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci
Teresa
T
UOC di Oncologia Medica, ASL Frosinone.
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000517:prevention & control / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D009363:Neoplasm Proteins; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole